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Before we get stuck into the debate, some basic informa-
tion needs to be provided. Dissection of the aorta is a life-
threatening disease and is considered as “acute” when the
diagnosis is made within 2 weeks of the initial symptoms.
The deﬁnition of an acute dissection is even not uniform in
that several pathologies, such as intramural hematoma and
penetrating aortic ulcer that may evolve to a dissection, are
included.1 Acute dissection of the ascending aorta (DeBakey
I or II, or Stanford A), with an assumed mortality rate of 1e
2% per hour in the ﬁrst 24 hours of symptom onset requires
a prompt surgical therapy.2e4 Medical therapy alone in this
setting is associated with 50% mortality at 30 days in older
series,2 and has been reported to be lower with surgery.5
However, there is no evidence based on randomized
controlled trials (RCT) or comparative studies to answer this
question. According to the International Registry of acute
Aortic Dissection (IRAD) dissection of the aorta occurs in the
descending aorta (DeBakey III or Stanford B) in about 37%
of patients.4 Data from the IRAD registry are currently
setting a trend on the views of acute dissection, for both
type A and type B. This important register is multicentered
and has gathered details of numerous patients, adding very
useful information, such as predictors for mortality and
complications. However, several questions cannot be
answered by this register, like how many of the uncompli-
cated dissections will become complicated and how stan-
dardized the different therapy options are. No information
is provided regarding hypertension control. These are
extremely important questions for initial decision-making.
Although acute type B dissection carries a lower initial
overall mortality than type A dissections, with about 10%
deaths within 30 days, the diagnosis can be difﬁcultdand
sometimes even delayeddowing to multiple possible
symptoms. The outcome of type B dissections is related to
the clinical presentation and can be worsened by severe
life-threatening complications. The most common ones are
death, rupture, malperfusion, retrograde dissection into the
ascending aorta, refractory pain, and, in the long run, aortic
dilatation and aneurysm formation.6,7 Occurrence of at
least one of those conditions thus makes a dissection
“complicated.” About 30% of acute type B aortic dissections
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death,8e11 but we do not know which patient will get these
complications. In addition to these early complications,
aneurysmal evolution occurred within 5 years in 20e50% of
the patients who had survived the acute phase,11,12 and
these are the complications that we aim to prevent. IRAD
data have shown that the most common cause of death is
rupture (40%) followed by intestinal ischemia (17e39%).5BEST MEDICAL TREATMENT
Although not scientiﬁcally proven, but based on good clin-
ical practice, there is a general agreement that patients with
an initially uncomplicated BAD should receive medical
therapy with close monitoring of blood pressure to
decrease the shear forces on the aortic wall. Basic medical
treatment comprises b-blockers, diuretics, calcium-blockers,
and angiotensin converting enzyme-inhibitors withdin the
acute phasedadditional a-blockers, as well as nitroglyc-
erine. The primary aim of this approach is to obtain a sys-
tolic blood pressure between 100 and 120 mmHg, with the
maintenance of a urinary output and prevention of mal-
perfusion of the visceral organs. In a series of 171 cases of
acute BAD with a median follow-up of 2.3 years, Kodama
et al.13 found that, although use of b-blockers did not itself
affect outcomes, heart rate control was associated with a
signiﬁcant reduction in overall aortic complications (12.5%
vs. 36% in controls). Meanwhile, current data revealed a
mortality rate of medically-treated BAD of around 10%
within the ﬁrst month. From the IRAD data it could be
concluded that calcium channel-blockers were correlated
with a better survival during follow-up in BAD, whereas b-
blockers improved the outcome after surgery for type A
aortic dissections.14,15 These conﬂicting data need to be
clariﬁed in future RCTs using b-blockers and calcium
channel-blockers in patients with only type B dissections
leaving type A dissection patients for a separate study.
The same confusion exists when addressing the long-
term survival of patients with BAD. In this context, only
one publication from Sweden has shown that after surviving
the ﬁrst month, the long-term survival was not different
from that of the general population,16 whereas other au-
thors have reported a signiﬁcant number of complications
with 48e82% survival at 5 years. IRAD data have conﬁrmed
this trend by showing that 189 consecutive patients with
acute BAD, who were successfully discharged alive following
medical therapy, had a 3-year survival of 78%.17 In this
setting, 25e50% of patients treated medically will develop
late aortic-related complications with the need for an
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information on the survival of patients with type B
dissections.THORACIC ENDOVASCULAR AORTIC REPAIR (TEVAR)
Endovascular repair is a well-known alternative to open
repair for the treatment of abdominal aortic aneurysm,
supported by two initial European prospective, randomized
trials (Dutch Randomised Endovascular Aneurysm Man-
agement [DREAM], Endovascular Aneurysm Repair
[EVAR]).18e20 Accordingly, but despite the lack of RCTs, the
use of stent grafts has been introduced, and have been
reported to be favorable in thoracic aortic aneurysms and in
traumatic thoracic aortic ruptures.21e23 Since the ﬁrst
report of thoracic endovascular aortic repair (TEVAR) in
aortic dissections by Dake et al. in 1999,24 several cohort
studies have demonstrated feasibility and efﬁcacy, but so
far there is no RCT of TEVAR for the treatment of acute
complicated type B dissection, although non-randomized
studies suggested lower mortality rates when compared
with open surgery.24e26 It is true that the results of stents
or fenestration procedures for treating vascular malperfu-
sion caused by BAD are encouraging with respect to vessel
patency, but not to mortality.27e30 However, all these series
are retrospective and without a control group of patients,
and, subsequently, their scientiﬁc evidence is low.
We have shown in our updated meta-analysis of TEVAR
for predominantly acute uncomplicated BAD an average
weighted 30-day mortality of 10.0% (68 studies, 1,685 pa-
tients), and a late mortality with a weighted average event
rate of 11% (63 studies, 1,609 patients), suggesting that
TEVAR may also be beneﬁcial in these cases. Our meta-
analysis of four single-arm studies with a total of 501 pa-
tients regarding best medical treatment (BMT) for uncom-
plicated BAD showed an average weighted rate for late
mortality or late complications of 13.8% and a 30-day
mortality of 11% (seven studies, 962 patients). However,
these data cannot be used as evidence as the numbers were
small and a control group was lacking.
Another meta-analysis of four non-randomized studies
each comparing TEVAR with BMT for complicated BAD (292
patients with medical treatment and 141 patients with
TEVAR) showed no signiﬁcant difference between the two
therapeutic options. Again, these data are of limited value
owing to the limited number of patients and the non-
randomized study design.
Regarding uncomplicated chronic BAD, the results of a
randomized trial comparing TEVAR with BMT after 2 weeks
were recently published (Investigation of STEnt Grafts in
Aortic Dissection [INSTEAD] trial).31 This trial showed that
when the stent graft was placed between 2 weeks and 1
year after the onset of the acute dissection, TEVAR did not
do better than BMT on 2-year all-cause or aortic related
mortality. Even if underpowered for mortality, the INSTEAD
trial has shown that there was a remodeling of the aorta
leading to an enlarged true lumen with regression of the
false lumen. Aortic remodeling with thrombosis of thethoracic false lumen occurred in 91.3% of patients with
TEVAR versus 19.4% of patients with BMT.
There are arguments against the use of stent grafts in the
vulnerable dissected aorta, but the INSTEAD trial clearly
showed that TEVAR was not associated with a higher
mortality than BMT in chronic uncomplicated BAD. We are
awaiting the publication of the long-term follow-up results,
which, when orally presented, has shown a better survival
of the TEVAR group than the BMT group. Accordingly,
TEVAR might be a better therapeutic option than BMT
alone for 20e30% of patients with uncomplicated BAD that
will develop an aneurysmal dilatation of the false lumen,
requiring late surgical intervention. The reason might be
found in the hazard of having a patent false lumen, which
was described by Akutsu et al.,32 who found a higher
mortality rate in patients with a patent false lumen than in
those with a thrombosed one. In this setting, a multivariate
analysis has shown that baseline maximum descending
aortic diameter, proximal location, and size of the entry tear
were predictors of related adverse events, whereas mor-
tality was predicted by the maximum diameter of the
descending thoracic aorta, entry tear size, and Marfan
syndrome.33 These results again underline the need for a
prospective RCT to study the long-term result of
TEVAR þ BMT versus BMT alone in patients with BAD.
Following the review of the available data, what
evidence-based concept do we have for the treatment of
acute uncomplicated type B dissection? Absolutely none!
All our knowledge is based on a large, but heterogeneous,
registry of type A and type B dissectionsdthe results of
which demonstrate the risk of false lumen enlarge-
mentdand one RCT on chronic uncomplicated type B dis-
sections, which demonstrates the safety of TEVAR for
treating the dissected aorta, leading to thrombosis of the
false lumen. What advantage is there in treating a dissec-
tion in the ﬁrst 2 weeks after the initial event where no
remodeling processes or stabilization of the aortic wall
layers have occurred? Covering the entry tear of acute type
B dissections and thereby causing a thrombosis of the false
lumen in an early phase of the disease could be the solution
to avoiding late lumen enlargement, as well as treating
some malperfusion complications, as observed in our own
clinical practice.
Currently, there is no level I evidence to support the
routine use of TEVAR for DeBakey III dissections, and there
is no level I evidence for medical treatment either. The need
for interventions in uncomplicated BAD is characterized by a
paucity of relevant data, most of them being derived from
TEVAR in complicated aortic dissections, where mortality
for TEVAR is in the same range as BMT for uncomplicated
dissections. But are we comparing the same patients? It is
likely that the two cohorts are very different. Furthermore,
the treatment paradigm still under use, which advocates
intervention only in the complicated cases, is derived from
those times when open surgery had a worse risk-to-beneﬁt
ratio than medical therapy. Today, with the evolution of
TEVAR and improved stent grafts, standardization of TEVAR
might shift the risk-to-beneﬁt ratio in favor of early
276 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 3 September/2013intervention. For obvious reasons, though, this needs to be
scientiﬁcally proven. The European “Acute Dissection Stent-
graft Or Best medical treatment” (ADSORB) study, which is
evaluating TEVAR þ BMT versus BMT alone in patients with
acute uncomplicated BAD, has completed its enrolment,
and the results of the study are urgently needed to deter-
mine the best way to treat this potentially lethal disease.34REFERENCES
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